Full-Time

Principal Specialist

Quality Assurance Compliance

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

No salary listed

Senior

Melbourne VIC, Australia

This position is site-based, requiring you to be at Moderna’s site full-time. This position is not eligible for remote work.

Category
QA & Testing
Quality Assurance
Requirements
  • Bachelor’s degree in a relevant field (e.g., Life Sciences, Engineering, Quality, Regulatory Compliance) or equivalent experience.
  • > 5 years of pharmaceutical or related work experience with emphasis on current Good Manufacturing Practices.
  • This position is site-based, requiring you to be at Moderna’s site full-time. This position is not eligible for remote work.
Responsibilities
  • Maintain Moderna’s QMS, ensuring compliance with evolving regulatory requirements and industry best practices.
  • Support deviation management, change control, gap analysis, risk assessments, and compliance reporting, ensuring proper documentation and timely resolution.
  • Oversee records management, Annual Product Quality Reviews (APQRs), training documentation, and compliance tracking to sustain regulatory adherence across the site.
  • Participate in internal audits and inspection readiness activities, contributing to preparation for regulatory inspections.
  • Collaborate with quality, operations, and regulatory teams to ensure continued compliance with evolving industry standards.
  • Identifying opportunities for process improvements and contributing to initiatives that enhance the efficiency and effectiveness of Moderna’s QMS.
  • Acting as a key support resource for compliance-related activities, providing documentation, reports, and guidance as needed.
  • Supporting a culture of quality across the site by fostering collaboration and ensuring best practices in QMS application.
Desired Qualifications
  • Experience in QMR, Quality Management Systems (QMS), Change control, Deviations management, GXP compliance, or pharmaceutical/biotech regulations is desirable.
  • Experience in a Quality or Compliance role in the pharmaceutical industry preferred.
  • Strong attention to detail, organizational skills, and ability to manage multiple priorities.
  • Excellent communication and problem-solving skills.
  • Ability to collaborate across teams and contribute to a culture of continuous improvement.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treating diseases. Unlike traditional methods that often rely on proteins or viruses, Moderna's mRNA technology allows for a more flexible and efficient way to develop and manufacture drugs. The company's goal is to harness the power of mRNA to improve patient outcomes and transform the landscape of medicine.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's mRESVIA vaccine approved in Australia and UK for RSV prevention in older adults.
  • The biomanufacturing training program with Bioversity and MCPHS enhances workforce skills.
  • Moderna's next-gen COVID and flu/COVID vaccines diversify its product portfolio.

What critics are saying

  • Moderna faces a bribery scandal related to COVID-19 vaccine trials.
  • The patent lawsuit with Pfizer and BioNTech could lead to financial liabilities.
  • Moderna reported a net loss of $3.6 billion in 2024, raising financial stability concerns.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for new categories of medicines.
  • The company focuses on mRNA vaccines beyond COVID-19, like RSV and flu/COVID combo.
  • Moderna collaborates with Merck on a personalized cancer vaccine, launching in 2027.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

5%
Slay News
Apr 27th, 2025
Moderna Faces Ban for Bribing Children to Join Covid 'Vaccine' Trials

Moderna could face suspension over the practices deemed "unacceptable" by regulators.

Notas de Prensa
Apr 7th, 2025
Moderna to showcase its extensive research on Infectious Diseases at ESCMID 2025.

Moderna, Inc. (NASDAQ:MRNA) announces that it will present at the World Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), which will be held in Vienna, Austria, from April 11 to 15, 2025, its research in multiple areas of infectious diseases, such as COVID-19, influenza, respiratory syncytial virus, cytomegalovirus, norovirus, and mpox.

PharmiWeb
Mar 31st, 2025
Moderna Receives Australian Therapeutic Goods Administration Approval For Rsv Vaccine For Older Adults

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older.1 mRESVIA's approval marks a significant milestone as it is the first mRNA vaccine in Australia approved for use against a disease beyond COVID-19."We are pleased to receive regulatory approval for mRESVIA in Australia following the TGA's decision," said Stéphane Bancel, Chief Executive Officer of Moderna. "This approval underscores our commitment to protecting older adults from RSV-related respiratory diseases. We look forward to supplying mRESVIA from our Melbourne facility to older Australians vulnerable to RSV in the future."RSV is a highly contagious respiratory virus that causes a substantial burden of disease, particularly in older adults. In the 2024 Australian winter period, RSV laboratory-notified cases in adults aged 65 and older were nearly two-thirds the number of influenza cases in the same age group.2 90% of RSV-related deaths reported nationally occurred in those aged 60 years and older, underscoring its potential for severe impact on older Australians.2The approval is based on positive data from the Phase 3 clinical trial ConquerRSV, a randomized, placebo-controlled, observer-blind, case-driven clinical study conducted in approximately 37,000 adults aged 60 years or older in 22 countries.About mRESVIA (Respiratory Syncytial Virus Vaccine)mRNA-1345 is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells

PharmiWeb
Mar 28th, 2025
Moderna Receives Medicines And Healthcare Products Regulatory Agency Marketing Authorization In The Uk For Rsv Vaccine

mRESVIA® is Moderna's second approved product in the UKCAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older."The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our RSV vaccine will be manufactured at the Moderna Innovation and Technology Centre in Oxfordshire, which will be fully operational later this year."RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia. In the UK, RSV has an impact on elderly adults and is responsible for 175,000 GP appointments, 14,000 hospitalizations, and 8,000 deaths in adults 65 years of age and older per year.[i]"Given the serious consequences of RSV for older people, which can lead to hospitalization and severe outcomes, we are delighted that the MHRA has authorized our RSV vaccine," said Darius Hughes, UK General Manager of Moderna. "With the MHRA decision, mRESVIA becomes Moderna's second approved product in the UK, further demonstrating the role of mRNA vaccines in helping to protect the public from respiratory diseases."The approval is based on positive data from the Phase 3 clinical trial ConquerRSV , a randomized, placebo-controlled, observer-blind, case-driven clinical study conducted in approximately 37,000 adults aged 60 years or older in 22 countries. No serious safety concerns were identified in the Phase 3 trial.About mRNA-1345 (Respiratory Syncytial Virus Vaccine)mRNA-1345 is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein

Bioversity International
Mar 27th, 2025
Bioversity and the Massachusetts College of Pharmacy and Health Sciences (MCPHS) Launch New Biomanufacturing Training Program in Collaboration with Moderna

Bioversity and the Massachusetts College of Pharmacy and Health Sciences (MCPHS) launch new biomanufacturing training program in collaboration with Moderna.